A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy.

Trial Profile

A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Apr 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Planned end date changed from 1 Jun 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top